Publicacións en colaboración con investigadores/as de McGill University Health Centre (7)

2024

  1. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

  2. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

    Nature communications, Vol. 15, Núm. 1, pp. 3083

2023

  1. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

    The Lancet Infectious Diseases, Vol. 23, Núm. 7, pp. 856-866

2022

  1. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

    Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520

2021

  1. Empagliflozin in heart failure with a preserved ejection fraction

    New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461

2020

  1. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

    European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392

2019

  1. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

    Nature Communications, Vol. 10, Núm. 1